Last reviewed · How we verify
Intrathecal triple
Intrathecal triple is a combination chemotherapy regimen administered directly into the cerebrospinal fluid to treat hematologic malignancies and prevent or treat central nervous system involvement.
Intrathecal triple is a combination chemotherapy regimen administered directly into the cerebrospinal fluid to treat hematologic malignancies and prevent or treat central nervous system involvement. Used for Acute lymphoblastic leukemia (ALL) with CNS involvement or CNS prophylaxis, Acute myeloid leukemia (AML) with CNS involvement, Lymphoma with meningeal involvement.
At a glance
| Generic name | Intrathecal triple |
|---|---|
| Also known as | DepoCyte, DepoCyt, Precortalon, Di-Adreson-F, Cytarabine |
| Sponsor | Nordic Society for Pediatric Hematology and Oncology |
| Drug class | Intrathecal chemotherapy combination |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This intrathecal formulation typically combines three chemotherapy agents (commonly methotrexate, cytarabine, and hydrocortisone) delivered directly into the cerebrospinal fluid via lumbar puncture or ventricular access. The direct CNS delivery achieves high local drug concentrations while minimizing systemic toxicity, targeting leukemic or lymphomatous cells in the central nervous system and meninges.
Approved indications
- Acute lymphoblastic leukemia (ALL) with CNS involvement or CNS prophylaxis
- Acute myeloid leukemia (AML) with CNS involvement
- Lymphoma with meningeal involvement
Common side effects
- Chemical arachnoiditis
- Neurotoxicity
- Headache
- Myelosuppression
- Infection at injection site
Key clinical trials
- Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (PHASE3)
- LBL-2016 for Children or Adolescents in China (PHASE3)
- Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (PHASE4)
- Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) (PHASE2)
- Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma (PHASE2)
- Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia (PHASE2)
- A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) (PHASE1)
- Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intrathecal triple CI brief — competitive landscape report
- Intrathecal triple updates RSS · CI watch RSS
- Nordic Society for Pediatric Hematology and Oncology portfolio CI